United States Patent 8,445,013: Scope, Claims, and Patent Landscape for Oral Ethyl Eicosapentaenoate (TG Reduction in High-Baseline Patients)
What does US 8,445,013 claim in plain scope terms?
US 8,445,013 is a method-of-use claim set for reducing triglycerides (TGs) in a specific population defined by high fasting baseline triglycerides and treated with oral, daily ethyl eicosapentaenoate for 12 weeks at a defined dose range.
Across the independent claim and dependents, the scope is anchored by four technical pillars:
- Population: fasting baseline triglycerides ≥ about 500 mg/dL.
- Regimen: daily oral administration for 12 weeks.
- Active and dose: ethyl eicosapentaenoate in a capsule formulation, 2000 mg to about 5000 mg per day.
- Outcome: TG reduction vs a comparator subject (no treatment) with defined magnitude thresholds, and with LDL-C non-increase requirements in select dependents.
Claim 1 is the anchor scope (population + regimen + dose + comparative efficacy)
Claim 1 recites a method:
- reducing triglycerides in a subject with fasting TG ≥ about 500 mg/dL
- by orally administering daily for 12 weeks
- a pharmaceutical composition comprising 2000 mg to about 5000 mg ethyl eicosapentaenoate (in capsules)
- to achieve a TG reduction ≥ about 20% compared to a second subject with same fasting TG threshold who has not received the composition.
Dependent claims tighten phenotype and performance constraints
- Claim 2 adds lipid-parameter context: median fasting LDL-C between ~50 and ~300 mg/dL for both subject and comparator.
- Claim 3 layers additional baseline ranges (non-HDL-C, total cholesterol, VLDL-C, HDL-C). It is a multi-marker baseline definition that further narrows eligible subjects and/or the claimed study population.
- Claims 4 and 5 add a safety/performance constraint: TG reduction with no LDL-C increase, at thresholds ≥25% and ≥30%, respectively.
- Claim 6 expands outcome readout beyond TG to VLDL-C reduction (vs comparator), tied to the same core regimen concept of Claim 1.
What is the exact claim scope by element (dosing, duration, endpoint, comparison)?
Below is the element-by-element scope map.
| Claim element |
Claim 1 requirement |
Dependent refinements |
| Subject baseline TG |
fasting TG ≥ ~500 mg/dL |
All dependents inherit |
| Comparator design |
comparator subject with same TG baseline who has not received composition |
Inherited across all dependents |
| Route |
Oral |
Inherited |
| Dosing frequency |
Daily |
Inherited |
| Duration |
12 weeks |
Inherited |
| Active |
Ethyl eicosapentaenoate |
Inherited |
| Dose per day |
2000 mg to ~5000 mg |
Inherited |
| Formulation |
one or more capsules |
Inherited |
| Primary efficacy endpoint |
TG reduction ≥ ~20% vs comparator |
Claims 4 and 5 increase TG reduction threshold |
| LDL-C constraint |
Not in Claim 1 |
Claim 4: TG ≥25% with no LDL-C increase. Claim 5: TG ≥30% with no LDL-C increase |
| Baseline lipid phenotype |
Not in Claim 1 |
Claim 2: LDL-C median ~50-300 mg/dL. Claim 3: adds non-HDL-C, total cholesterol, VLDL-C, HDL-C median ranges |
| Secondary efficacy endpoint |
Not specified |
Claim 6: VLDL-C reduction vs comparator |
How broad is the “method” claim with respect to patient selection?
The strongest breadth driver is the baseline TG criterion in Claim 1: TG ≥ ~500 mg/dL. That is a wide eligibility gate because many hypertriglyceridemia populations can meet that threshold, including both familial and multifactorial etiologies.
However, the dependents narrow patient characterization:
- LDL-C median window (Claim 2) and
- a multi-analyte baseline lipid panel (Claim 3).
Those dependents function as additional limiting features. In enforcement terms, they require the accused method to fall within the defined baseline distributions or to demonstrate them in the relevant study population (depending on how infringement is litigated in the jurisdiction).
How broad is the dosing and formulation scope?
Claim 1 covers:
- 2000 mg to ~5000 mg/day ethyl eicosapentaenoate
- present in one or more capsules
- administered daily for 12 weeks.
Key points:
- The lower bound at 2000 mg/day captures conventional high-dose ethyl eicosapentaenoate regimens.
- The upper bound at ~5000 mg/day creates room for higher-than-standard dosing strategies without exiting the claim.
- “One or more capsules” is permissive. It does not restrict capsule count, segmentation, or total capsule number per day, so long as the formulation is capsule-based.
What performance thresholds are claimed?
Two distinct TG reduction strata appear in the dependents, both tied to “no LDL-C increase”:
- Claim 4: TG reduction ≥ ~25% at 12 weeks, with no LDL-C increase vs comparator.
- Claim 5: TG reduction ≥ ~30% at 12 weeks, with no LDL-C increase vs comparator.
The independent claim uses a lower TG threshold:
- Claim 1: TG reduction ≥ ~20% at 12 weeks vs comparator.
For secondary outcomes:
- Claim 6: requires VLDL-C reduction vs comparator (no magnitude threshold stated in the excerpt you provided).
What does the “compared to a second subject who has not received” language do to infringement risk?
Claim 1 is written as a comparative method. That structure can affect proof:
- The method is tied to demonstrating an effect relative to an untreated comparator cohort.
- In litigation, an accused therapy typically must be evaluated in a way that satisfies the comparative framework, either through study design similarities or through statistical equivalence to a “not treated” comparator.
Practically, the claim is still a therapeutic effect claim. But the comparative structure can raise evidentiary and trial-design alignment issues for both patentee and defendant.
Where does US 8,445,013 sit in the broader ethyl eicosapentaenoate patent landscape?
You provided only the claims excerpt, not the patent specification, priority chain, file history, or citations. Without those, the landscape assessment can only be performed at a structural level: what kinds of other patents typically surround these claims and how Claim 1’s key limitations create “claim fences.”
Claim fence 1: High TG baseline (≥ ~500 mg/dL)
This is narrower than general hypertriglyceridemia indications that cover modest TG elevations. Many ethyl eicosapentaenoate patents and uses focus on broader dyslipidemia endpoints (TGs broadly, non-HDL-C, CV risk, etc.). By requiring fasting TG ≥ 500 mg/dL, US 8,445,013 targets severe hypertriglyceridemia phenotypes.
Claim fence 2: 12-week duration
Many lipid studies use 8 or 6 weeks, or endpoints at different timepoints. Here the duration is a defined part of the method. If a competitor runs a study and claims use at a different duration, it may avoid literal satisfaction of the “12 weeks” requirement (subject to doctrine of equivalents and how “method of reducing” is proven in the forum).
Claim fence 3: Dose range 2000–5000 mg/day
This defines a dosing envelope. If another patent claims a lower dose regimen or a higher dose regimen outside the range, it may not read directly onto Claim 1.
Claim fence 4: Comparative thresholding (≥20% TG; ≥25/30% TG with no LDL-C increase)
This is a mechanistic performance claim, not just a dosing prescription.
- A treatment that reduces TG but increases LDL-C may fall outside Claims 4 and 5.
- A treatment that reduces TG by less than the claimed percentage threshold may avoid these dependents, while still potentially implicating Claim 1 if it clears ≥20%.
Claim fence 5: Capsule formulation
Many ethyl eicosapentaenoate products are capsule-based. The claim does not constrain excipients or manufacturing. It is primarily a dosage form requirement that may still cover most marketed forms.
How could other patents overlap or differ (structural comparators)?
Below are the most common “neighbor” claim categories that typically intersect with ethyl eicosapentaenoate TG-reduction claims, expressed as structural differences.
-
Different patient stratification
- Neighbor patents may define baseline TG at a lower threshold (for example, ≥150 or ≥200 mg/dL).
- Such claims often overlap the efficacy concept but may not infringe because US 8,445,013 requires ≥ ~500 mg/dL.
-
Different endpoint hierarchy
- Some patents claim reductions in non-HDL-C or CV outcomes rather than TG reduction magnitude.
- US 8,445,013 specifically uses TG reduction ≥20% and, in dependents, TG with no LDL-C increase and VLDL-C reduction.
-
Different timepoints
- Neighbor patents may use 24 weeks or 52 weeks.
- A clinician’s real-world use could still land in the 12-week window, but infringement analysis would hinge on how “daily for 12 weeks” is interpreted.
-
Different dosing regimens
- Some patents tie to fixed dosing schedules (exact mg/day or exact number of capsules) or different dose splitting.
- US 8,445,013 uses a range: 2000 to ~5000 mg/day.
-
Different lipid safety claims
- Claims 4 and 5 explicitly require no LDL-C increase while achieving higher TG reductions.
- If an accused method increases LDL-C but decreases TG, it may miss the dependent claims.
Practical claim interpretation for commercial strategy
From a freedom-to-operate perspective, US 8,445,013 is strongest against commercial activities that combine:
- a severe hypertriglyceridemia target population (fasting TG ≥500 mg/dL),
- an ethyl eicosapentaenoate daily regimen within 2000–5000 mg,
- administered over 12 weeks,
- and supported by outcome data showing TG reduction magnitude and (for dependent claims) lack of LDL-C increase.
This structure makes the patent most likely to be implicated by:
- trial protocols designed around TG reduction endpoints at 12 weeks; and
- labeling or promotional claims that track the same thresholds.
Conversely, strategies that may reduce risk are those that shift at least one hard claim element:
- patient baseline (below the ≥500 mg/dL gate),
- regimen duration (not “12 weeks”),
- or dose outside the 2000–5000 mg band.
Does the claim set cover all ethyl eicosapentaenoate TG-lowering uses?
No. US 8,445,013 does not read broadly on every ethyl eicosapentaenoate TG effect. It is limited by:
- fasting TG threshold,
- capsule daily regimen over a defined duration,
- defined dose range,
- and defined TG/VLDL-C performance benchmarks (and LDL-C non-increase for Claims 4 and 5).
Key Takeaways
- US 8,445,013 is a tightly elemented method-of-use patent for oral ethyl eicosapentaenoate in severe hypertriglyceridemia, defined by fasting TG ≥ ~500 mg/dL.
- Claim 1 covers 12-week daily capsule dosing of 2000–~5000 mg/day ethyl eicosapentaenoate with ≥~20% TG reduction versus an untreated comparator with similar TG baselines.
- Claims 4 and 5 add a safety-performance constraint: ≥~25% or ≥~30% TG reduction without LDL-C increase.
- Claims 2 and 3 narrow subject lipid phenotypes through median baseline LDL-C and multi-analyte baseline lipid ranges.
- Claim 6 adds VLDL-C reduction as an additional efficacy readout.
- The patent’s “claim fences” are the baseline TG gate, 12-week duration, dose range, and outcome thresholds, which are the pivot points that determine overlap with other ethyl eicosapentaenoate patents and commercial trial/labeling strategies.
FAQs
-
What is the minimum ethyl eicosapentaenoate daily dose covered by US 8,445,013?
2000 mg/day (Claim 1).
-
What is the fixed treatment duration required for infringement of Claim 1?
12 weeks of daily oral administration (Claim 1).
-
What triglyceride reduction magnitude is required in Claim 1?
At least about 20% TG reduction vs an untreated comparator with fasting TG ≥ about 500 mg/dL (Claim 1).
-
Which claims require “no increase in LDL-C” and at what TG thresholds?
Claims 4 and 5 require no LDL-C increase while achieving TG reductions of at least about 25% (Claim 4) and at least about 30% (Claim 5).
-
Does the patent cover VLDL-C reduction specifically?
Yes, Claim 6 recites reduction in VLDL-C compared to the untreated comparator.
References
- User-provided claim text for US 8,445,013 (Claims 1-6).
